Clinical Data Management Applications & Studies

41. Large PMA Study Of CRC Diagnostic 8/28/2019

    A study needed to enroll approximately 12,000 subjects and was also unique because it required subjects to self-collect samples at home. Read about the risk management and mitigation that Health Decisions utilized to keep the study on track.

42. Medical University Finds Solution To Track Participant Remuneration 7/15/2019

    Concern ensued across the Medical University of South Carolina (MUSC) research faculty and staff when they received notice that departments would need to somehow track and sum all their petty cash, Walmart and Target gift cards, VISA cards and checks issued through Accounts Payable (as there was no institutional research policy standardizing a single type of remuneration payment for clinical research participants). A fellow academic medical school recommended ClinCard by Greenphire which ended up being the perfect solution.

43. Real-Time Monitoring Of The Digital Patient In Clinical Trials 6/7/2019

    This poster reports a framework for the real-time monitoring of subjects using wearable and patient-centric devices from multiple vendors. Wearable technology is a key component in the design of more patient-centric clinical trials.

44. How A Top CRO Used ClinCard To Create A Personalized Patient Experience For A Non-interventional Psoriasis Study 4/15/2019

    The CRO realized that they needed to introduce new ways to keep participants engaged and interested if they were going to successfully support this trial. The CRO identified ClinCard as the ideal software that could instantly get study participants their stipends, without adding a burden on the site staff.

45. The Stakes Were High In This Phase II Study, But The Risk Was Under Control 4/17/2018

    Software solutions provider adds value for a midsize pharmaceutical company from a quality, cost and study governance perspective by enabling them to implement risk-based (dynamic) approaches to monitoring.

46. Achieving Clinical Operations Excellence 8/30/2017

    Learn how Revvity Signals Software clinical solutions give clinical operations organizations the unprecedented ability to reduce the time, cost and risk of running clinical trials while accelerating the time to market for products across the entire portfolio of clinical candidates.

47. Solutions For The Strategic Assessment Of Clinical Data In Trial Operations 8/29/2017

    Achieve clinical trial operations excellence using this an innovative solution that gives clinical operations organizations the unprecedented ability to reduce the time, cost, and risk of running clinical trials while accelerating time to market for products across the entire portfolio of clinical candidates.

48. eCOA Supports Successful Antianginal Trial 8/27/2017

    Gilead Sciences’ previous studies of Ranexa (ranolazine) relied on data from exercise treadmill parameters as the primary endpoint. But collecting data in this manner is costly, logistically challenging, and bears questionable clinical relevance — especially at the individual patient level. Learn how Gilead Sciences successfully utilized ERT handhelds to collect regulatory-compliant, patient-driven data in support of the primary efficacy endpoint in a Phase IV study of Ranexa.

49. Electronic Columbia Suicide Severity Rating Scale Included In A Wider Range Of Clinical Studies 8/25/2017

    The objective of this study was to compare the equivalence of a new version of the electronic Columbia-Suicide Severity Rating Scale that was administered on a tablet device. The results supported the validity and reliability of the new tablet-based electronic Columbia-Suicide Severity Rating Scale and allow its inclusion in a wider range of clinical studies, particularly where a tablet is also being used to collect other study data.

50. Celgene Leverages ERT eCOA Data for FDA Approval 8/24/2017

    A biopharmaceutical company wanted to determine whether patients treated with an oral inhibitor of phosphodieasterase-4 (PDE-4) would show improvement in signs and symptoms of PsA. They used ERT eCOA tablets to collect data about patient symptoms as observed by physicians through the ACR assessment which was used to assess efficacy. Results showed reduced monitoring time and costs, decreased time to database lock, and FDA approval.